Imaging and angiogenesis of malignant lymphoma with dynamic MRI, H-MRS, P-MRS and FDG-PET/CT for staging, mid treatment assessment and outcome.

Imaging and angiogenesis of malignant lymphoma with dynamic MRI, H-MRS, P-MRS and FDG-PET/CT for staging, mid treatment assessment and outcome. - CILA

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON35043

Enrollment

Registered

2010-06-17

Start date

2010-09-06

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer of the lynphatic system Malignant lymphoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • >= 18 years. • WHO performance status: 0-3 (see appendix 1) • Karnofsky score >= 80 (see appendix 2) • Biopsy proven de novo or relapsed malignant lymphoma of any histological subtype. Relapsed patients who participated in this study during an earlier line of treatment may be re-entered in the study when fulfilling the inclusion criteria. • Sufficient biopsy material present to perform anti-CD34 staining and subsequent MVD assessment.

Exclusion criteria

Exclusion criteria: • Other active malignancy (less than 5 years in complete remission) except skin carcinoma (non-melanoma). • HIV positive patients. • Patients with contra-indications for contrast enhanced MR exams: o Claustrophobia, o Cardiac pacemaker or pacemaker wiring in situ, o Cerebral clips or metal artificial cardiac valves, o Ossicle prosthesis o Renal failure • Pregnancy or breastfeeding . • No staging FDG-PET/CT available. • Inability of giving informed consent.

Design outcomes

Primary

Measure	Time frame
Correlation between DCE-MRI and MVD of malignant lymphoma tissue. Correlation between MRS and response to treatment. Correlation between MRS and vascularisation.	—

Secondary

Measure	Time frame
Evaluation of the correlation between FDG-PET/CT parameters, DCE-MRI parameters and the changes during treatment.	—

Countries

Netherlands

Outcome results